United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,676,831.88. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

James Edgemond also recently made the following trade(s):

• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total transaction of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total transaction of $209,609.40.

United Therapeutics Price Performance

UTHR stock opened at $556.82 on Friday. The business has a fifty day moving average price of $566.51 and a 200-day moving average price of $515.84. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock has a market capitalization of $23.64 billion, a P/E ratio of 20.55, a P/E/G ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the firm earned $6.63 earnings per share. The firm’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, analysts anticipate that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, HC Wainwright lifted their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC lifted its position in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after purchasing an additional 70,829 shares during the last quarter. Finally, Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the 3rd quarter worth $317,617,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.